Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model

BMB Reports

Volumn 47, Issue 4, 2014, Pages 215-220

  Kwon, Sanghoon ^a   Kim, Young Eun ^b   Park, Jeong A ^b   Kim, Doo Sik ^c   Kwon, Hyung Joo ^a   Lee, Younghee ^b  

^a Hallym University   (South Korea)

^b Chungbuk National University   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Animal model; Colon cancer; Peptide vaccine; Therapeutics; TM4SF5

Indexed keywords

CANCER VACCINE; MEMBRANE PROTEIN; TM4SF5 PROTEIN, MOUSE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG SCREENING; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANIMALS; CANCER VACCINES; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899624243     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.4.157     Document Type: Article

References (30)

1. Abbas, A., Lichtman, A. and Pillai, S. (2010) Cellular and molecular immunology, 6th ed., pp. 351-373, Saunders, Elsevier, Philadelphia, U.S.A.
2. Aly, H. A. (2012) Cancer therapy and vaccination. J. Immunol. Methods 382, 1-23.
3. Montomoli, E., Piccirella, S., Khadang, B., Mennitto, E., Camerini, R. and De Rosa, A. (2011) Current adjuvants and new perspectives in vaccine formulation. Expert. Rev. Vaccines 10, 1053-1061.
4. Krieg, A. M. (2002) CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760.
5. Klinman, D. M., Currie, D., Gursel I and Verthelyi D. (2004) Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201-216.
6. Bode, C., Zhao, G., Steinhagen, F., Kinjo, T. and Klinman, D. M. (2011) CpG DNA as a vaccine adjuvant. Expert. Rev. Vaccines 10, 499-511.
7. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. and Krieg, A. M. (1998) CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876.
8. Carson, D. A. and Raz, E. (1997) Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J. Exp. Med. 186, 1621-1622.
9. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. and Harding, C. V. (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186, 1623-1631.
10. Lee, K. W., Jung, J., Lee, Y., Kim, T. Y., Choi, S. Y., Park, J., Kim, D. S. and Kwon, H. J. (2006) Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol. Immunol. 43, 2107-2118.
11. Kim, D., Kwon, S., Ahn, C. S., Lee, Y., Choi, S. Y., Park, J., Kwon, H. Y. and Kwon, H. J. (2011) Adjuvant effect of liposome- encapsulated natural phosphodiester CpG-DNA. BMB Rep. 44, 758-763.
12. Kim, D., Kwon, S., Rhee, J. W., Kim, K. D., Kim, Y. E., Park, C. S., Choi, M. J., Suh, J. G., Kim, D. S., Lee, Y. and Kwon, H. J. (2011) Production of antibodies with peptide- CpG-DNA-liposome complex without carriers. BMC Immunol. 12, 29.
13. Kim, D., Kwon, H. J. and Lee, Y. (2011) Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep. 44, 607-612.
14. Lee, Y. and Kwon, H. J. (2012) Production of epitope-specific antibodies using peptide-CpG-ODN-liposome complex without carriers and their application as a cancer vaccine in mice. Oncoimmunology. 1, 1215-1217.
15. Llovet, J. M. and Bruix, J. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327.
16. Tanaka, S. and Arii, S. (2011) Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J. Gastroenterol. 46, 289-296.
17. Muller-Pillasch, F., Wallrapp, C., Lacher, U., Friess, H., Buchler, M., Adler, G. and Gress, T. M. (1998) Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene 208, 25-30.
18. Lee, S. A., Lee, S. Y., Cho, I. H., Oh, M. A., Kang, E. S., Kim, Y. B., Seo, W. D., Choi, S., Nam, J. O., Tamamori-Adachi, M., Kitajima, S., Ye, S. K., Kim, S., Hwang, Y. J., Kim, I. S., Park, K. H. and Lee, J. W. (2008) Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J. Clin. Invest. 118, 1354-1366.
19. Lee, S. A., Ryu, H. W., Kim, Y. M., Choi, S., Lee, M. J., Kwak, T. K., Kim, H. J., Cho, M., Park, K. H. and Lee, J. W. (2009) Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 49, 1316-1325.
20. Kwon, S., Kim, D., Park, B. K., Cho, S., Kim, K. D., Kim, Y. E., Park, C. S., Ahn, H. J., Seo, J. N., Choi, K. C., Kim, D. S., Lee, Y. and Kwon, H. J. (2012) Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One. 7, e33121.
21. Kwon, S., Kim, D., Park, B. K., Wu, G., Park, M. C., Ha, Y. W., Kwon, H. J. and Lee, Y. (2013) Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncol. Rep. 29, 735-740.
22. Kwon, S., Kim, Y. E., Kim, D., Park, B. K., Wu, G., Kim, T. H., Choi, S. H., Kim, D. S., Kwon, H. J. and Lee, Y. (2013) Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model. Biochem. Biophys. Res. Commun. 435, 134-139.
23. Schreiber, T. H., Raez, L., Rosenblatt, J. D. and Podack, E. R. (2010) Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin. Immunol. 22, 105-112.
24. Yoshiji, H., Kuriyama, S., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H. and Fukui, H. (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 7, 1073-1078.
25. Choi, K. S., Bae, M. K., Jeong, J. W., Moon, H. E. and Kim, K. W. (2003) Hypoxia-induced angiogenesis during carcinogenesis. J. Biochem. Mol. Biol. 36, 120-127.
26. Mercurio, A. M., Lipscomb, E. A. and Bachelder, R. E. (2005) Non-angiogenic functions of VEGF in breast cancer. J. Mammary Gland Biol. Neoplasia. 10, 283-290.
27. Choi, S., Lee, S. A., Kwak, T. K., Kim, H. J., Lee, M. J., Ye, S. K., Kim, S. H., Kim, S. and Lee, J. W. (2009) Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood 113, 1845-1855.
28. Yoshiji, H., Kuriyama, S., Ways, D. K., Yoshii, J., Miyamoto, Y., Kawata, M., Ikenaka, Y., Tsujinoue, H., Nakatani, T., Shibuya, M. and Fukui, H. (1999) Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59, 4413-4418.
29. Kim, N. H., Park, H. J., Oh, M. K., and Kim, I. S. (2013) Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep. 46, 59-64.
30. Zhou, C., Shen, Q., Xue, J., Ji, C., and Chen, J. (2013) Overexpression of TTRAP inhibits cell growth and induces apoptosis in osteosarcoma cells. BMB Rep. 46, 113-118.